Literature DB >> 27210749

Oncogenic BRAF-Mediated Melanoma Cell Invasion.

Hezhe Lu1, Shujing Liu2, Gao Zhang3, Lawrence N Kwong4, Yueyao Zhu1, John P Miller4, Yi Hu5, Wenqun Zhong1, Jingwen Zeng1, Lawrence Wu3, Clemens Krepler3, Katrin Sproesser3, Min Xiao3, Wei Xu6, Giorgos C Karakousis7, Lynn M Schuchter6, Jeffery Field8, Paul J Zhang2, Meenhard Herlyn3, Xiaowei Xu9, Wei Guo10.   

Abstract

Melanoma patients with oncogenic BRAF(V600E) mutation have poor prognoses. While the role of BRAF(V600E) in tumorigenesis is well established, its involvement in metastasis that is clinically observed in melanoma patients remains a topic of debate. Here, we show that BRAF(V600E) melanoma cells have extensive invasion activity as assayed by the generation of F-actin and cortactin foci that mediate membrane protrusion, and degradation of the extracellular matrix (ECM). Inhibition of BRAF(V600E) blocks melanoma cell invasion. In a BRAF(V600E)-driven murine melanoma model or in patients' tumor biopsies, cortactin foci decrease upon inhibitor treatment. In addition, genome-wide expression analysis shows that a number of invadopodia-related genes are downregulated after BRAF(V600E) inhibition. Mechanistically, BRAF(V600E) induces phosphorylation of cortactin and the exocyst subunit Exo70 through ERK, which regulates actin dynamics and matrix metalloprotease secretion, respectively. Our results provide support for the role of BRAF(V600E) in metastasis and suggest that inhibiting invasion is a potential therapeutic strategy against melanoma.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  invadopodia; oncogenic BRAF; tumor invasion

Mesh:

Substances:

Year:  2016        PMID: 27210749      PMCID: PMC4889462          DOI: 10.1016/j.celrep.2016.04.073

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  56 in total

Review 1.  The Exocyst at a Glance.

Authors:  Bin Wu; Wei Guo
Journal:  J Cell Sci       Date:  2015-08-03       Impact factor: 5.285

2.  Exo70 isoform switching upon epithelial-mesenchymal transition mediates cancer cell invasion.

Authors:  Hezhe Lu; Jianglan Liu; Shujing Liu; Jingwen Zeng; Deqiang Ding; Russ P Carstens; Yusheng Cong; Xiaowei Xu; Wei Guo
Journal:  Dev Cell       Date:  2013-12-09       Impact factor: 12.270

3.  Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis.

Authors:  Hon S Leong; Amy E Robertson; Konstantin Stoletov; Sean J Leith; Curtis A Chin; Andrew E Chien; M Nicole Hague; Amber Ablack; Katia Carmine-Simmen; Victor A McPherson; Carl O Postenka; Eva A Turley; Sara A Courtneidge; Ann F Chambers; John D Lewis
Journal:  Cell Rep       Date:  2014-08-28       Impact factor: 9.423

4.  mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Authors:  William Damsky; Goran Micevic; Katrina Meeth; Viswanathan Muthusamy; David P Curley; Manjula Santhanakrishnan; Ildiko Erdelyi; James T Platt; Laura Huang; Nicholas Theodosakis; M Raza Zaidi; Scott Tighe; Michael A Davies; David Dankort; Martin McMahon; Glenn Merlino; Nabeel Bardeesy; Marcus Bosenberg
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

Review 5.  Invading one step at a time: the role of invadopodia in tumor metastasis.

Authors:  H Paz; N Pathak; J Yang
Journal:  Oncogene       Date:  2013-09-30       Impact factor: 9.867

6.  Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.

Authors:  Lawrence N Kwong; Genevieve M Boland; Dennie T Frederick; Timothy L Helms; Ahmad T Akid; John P Miller; Shan Jiang; Zachary A Cooper; Xingzhi Song; Sahil Seth; Jennifer Kamara; Alexei Protopopov; Gordon B Mills; Keith T Flaherty; Jennifer A Wargo; Lynda Chin
Journal:  J Clin Invest       Date:  2015-02-23       Impact factor: 14.808

7.  Cortactin phosphorylated by ERK1/2 localizes to sites of dynamic actin regulation and is required for carcinoma lamellipodia persistence.

Authors:  Laura C Kelley; Karen E Hayes; Amanda Gatesman Ammer; Karen H Martin; Scott A Weed
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

8.  BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

Authors:  Berta Sanchez-Laorden; Amaya Viros; Maria Romina Girotti; Malin Pedersen; Grazia Saturno; Alfonso Zambon; Dan Niculescu-Duvaz; Samra Turajlic; Andrew Hayes; Martin Gore; James Larkin; Paul Lorigan; Martin Cook; Caroline Springer; Richard Marais
Journal:  Sci Signal       Date:  2014-03-25       Impact factor: 8.192

9.  Endosomal WASH and exocyst complexes control exocytosis of MT1-MMP at invadopodia.

Authors:  Pedro Monteiro; Carine Rossé; Antonio Castro-Castro; Marie Irondelle; Emilie Lagoutte; Perrine Paul-Gilloteaux; Claire Desnos; Etienne Formstecher; François Darchen; David Perrais; Alexis Gautreau; Maud Hertzog; Philippe Chavrier
Journal:  J Cell Biol       Date:  2013-12-23       Impact factor: 10.539

10.  Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

Authors:  M S Carlino; L E Haydu; H Kakavand; A M Menzies; A L Hamilton; B Yu; C C Ng; W A Cooper; J F Thompson; R F Kefford; S A O'Toole; R A Scolyer; G V Long
Journal:  Br J Cancer       Date:  2014-06-10       Impact factor: 7.640

View more
  22 in total

Review 1.  Polarized Exocytosis.

Authors:  Jingwen Zeng; Shanshan Feng; Bin Wu; Wei Guo
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

Review 2.  The role of Exo70 in exocytosis and beyond.

Authors:  Yueyao Zhu; Bin Wu; Wei Guo
Journal:  Small GTPases       Date:  2017-06-19

3.  Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.

Authors:  Hanlin Zeng; Aparna Jorapur; A Hunter Shain; Ursula E Lang; Rodrigo Torres; Yuntian Zhang; Andrew S McNeal; Thomas Botton; Jue Lin; Matthew Donne; Ingmar N Bastian; Richard Yu; Jeffrey P North; Laura Pincus; Beth S Ruben; Nancy M Joseph; Iwei Yeh; Boris C Bastian; Robert L Judson
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

4.  FAM129B-dependent activation of NRF2 promotes an invasive phenotype in BRAF mutant melanoma cells.

Authors:  Cody J Schmidlin; Wang Tian; Matthew Dodson; Eli Chapman; Donna D Zhang
Journal:  Mol Carcinog       Date:  2021-03-08       Impact factor: 4.784

Review 5.  Melanin Transfer in the Epidermis: The Pursuit of Skin Pigmentation Control Mechanisms.

Authors:  Hugo Moreiras; Miguel C Seabra; Duarte C Barral
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

6.  Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity.

Authors:  Hongxin Huang; Guanjie Huang; Zhihong Tan; Yongfei Hu; Lin Shan; Jiajian Zhou; Xin Zhang; Shufeng Ma; Weiqi Lv; Tao Huang; Yuchen Liu; Dong Wang; Xiaoyang Zhao; Ying Lin; Zhili Rong
Journal:  BMC Biol       Date:  2022-04-25       Impact factor: 7.364

7.  Exo70 is an independent prognostic factor in colon cancer.

Authors:  Li Xiao; Kaifeng Zheng; Xia Lv; Jihuan Hou; Liang Xu; Yujie Zhao; Fei Song; Yaqiong Fan; Hanwei Cao; Wenqing Zhang; Xiaoting Hong; Yan-Yan Zhan; Tianhui Hu
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

Review 8.  Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.

Authors:  Wagner Ricardo Montor; Andrei Ronaldo Oliveira Silva Escartin Salas; Fabiana Henriques Machado de Melo
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

9.  LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway.

Authors:  Weiming Zhang; Li Yin; Guoxin Song; Xue Han; Zhiqiang Yin; Dan Luo
Journal:  Oncotarget       Date:  2017-12-05

10.  CD271 determines migratory properties of melanoma cells.

Authors:  Josefine Radke; Florian Roßner; Torben Redmer
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.